Iasis Molecular Sciences, Inc.
Mark Vachon is currently serving as the VP of Quality at Iasis Molecular Sciences, Inc., since January 2018. Prior to this role, Mark held various positions at Biogen from July 2008 to June 2017, including Sr. Associate roles where responsibilities involved managing QC contract labs, directing cGLP Viral Clearance Studies, and authoring regulatory documents. Mark's career at Biogen Idec spanned from 1992 to 2007, progressing through roles such as Associate III and Operator, focusing on manufacturing sciences and process development. Mark Vachon earned a Bachelor of Science degree in Biology from Framingham State University between 1982 and 1987.
This person is not in any teams
Iasis Molecular Sciences, Inc.
Iasis Molecular Sciences & Novion Technologies have pioneered and patented a family of technologies aimed at minimizing health care-acquired implantable medical device-related infection, wound infections associated with surgical procedures, and for the treatment of infection(s) and tissue loss associated with chronic wounds and burn trauma. Theproprietary antimicrobial agent technologies are of rational design, elegantly simple, and cost effective thus allowing patients of all ages and walks of life to benefit.Encouraging preclinical testing results have generated enthusiasm that they are on a path to providing value added, life-quality improving solutions for patients requiring implantable medical device therapies, those afflicted by topical infection, inflammation, and secondary tissue loss associated with burn trauma, periodontal disease, and abnormal healing such as with chronic wounds.